These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1991366)

  • 1. Effects of colestipol-niacin therapy on human femoral atherosclerosis.
    Blankenhorn DH; Azen SP; Crawford DW; Nessim SA; Sanmarco ME; Selzer RH; Shircore AM; Wickham EC
    Circulation; 1991 Feb; 83(2):438-47. PubMed ID: 1991366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
    Blankenhorn DH; Nessim SA; Johnson RL; Sanmarco ME; Azen SP; Cashin-Hemphill L
    JAMA; 1987 Jun; 257(23):3233-40. PubMed ID: 3295315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results.
    Blankenhorn DH; Johnson RL; Nessim SA; Azen SP; Sanmarco ME; Selzer RH
    Control Clin Trials; 1987 Dec; 8(4):356-87. PubMed ID: 3327654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
    Hodis HN
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect.
    Blankenhorn DH; Selzer RH; Mack WJ; Crawford DW; Pogoda J; Lee PL; Shircore AM; Azen SP
    Circulation; 1992 Dec; 86(6):1701-9. PubMed ID: 1451241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
    Cashin-Hemphill L; Mack WJ; Pogoda JM; Sanmarco ME; Azen SP; Blankenhorn DH
    JAMA; 1990 Dec; 264(23):3013-7. PubMed ID: 2243429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound.
    Blankenhorn DH; Selzer RH; Crawford DW; Barth JD; Liu CR; Liu CH; Mack WJ; Alaupovic P
    Circulation; 1993 Jul; 88(1):20-8. PubMed ID: 8319334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy.
    Mack WJ; Selzer RH; Hodis HN; Erickson JK; Liu CR; Liu CH; Crawford DW; Blankenhorn DH
    Stroke; 1993 Dec; 24(12):1779-83. PubMed ID: 8248954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cholesterol Lowering Atherosclerosis Study (CLAS): what it tells us about niacin/colestipol therapy.
    Hemphill LC
    J Clin Lipidol; 2015; 9(1):11-3. PubMed ID: 25670355
    [No Abstract]   [Full Text] [Related]  

  • 11. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
    Azen SP; Mack WJ; Cashin-Hemphill L; LaBree L; Shircore AM; Selzer RH; Blankenhorn DH; Hodis HN
    Circulation; 1996 Jan; 93(1):34-41. PubMed ID: 8616937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.
    Blankenhorn DH; Alaupovic P; Wickham E; Chin HP; Azen SP
    Circulation; 1990 Feb; 81(2):470-6. PubMed ID: 2404631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
    Zambon A; Hokanson JE; Brown BG; Brunzell JD
    Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints.
    Mack WJ; Xiang M; Shircore AM; Selzer RH; Hodis HN; Azen SP
    Cardiovasc Drugs Ther; 2000 Aug; 14(4):411-8. PubMed ID: 10999648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of human panelists in assessing coronary atherosclerosis.
    Azen SP; Cashin-Hemphill L; Pogoda J; Mack WJ; Sanmarco ME; Wickham E; Blankenhorn DH
    Arterioscler Thromb; 1991; 11(2):385-94. PubMed ID: 1998656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial quantitative coronary angiography and coronary events.
    Mack WJ; Xiang M; Selzer RH; Hodis HN
    Am Heart J; 2000 Jun; 139(6):993-9. PubMed ID: 10827379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis.
    Hodis HN; Mack WJ; LaBree L; Cashin-Hemphill L; Sevanian A; Johnson R; Azen SP
    JAMA; 1995 Jun; 273(23):1849-54. PubMed ID: 7776501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials.
    Mack WJ; Selzer RH; Pogoda JM; Lee PL; Shircore AM; Azen SP; Blankenhorn DH
    Arterioscler Thromb; 1992 Mar; 12(3):348-56. PubMed ID: 1547194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
    Frick MH; Syvänne M; Nieminen MS; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Taskinen MR
    Circulation; 1997 Oct; 96(7):2137-43. PubMed ID: 9337181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis.
    Glueck CJ
    Ann Intern Med; 1982 Apr; 96(4):475-82. PubMed ID: 7039445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.